Etanercept was developed by researchers at Immunex, and was released for commercial use in late 1998, soon after the release of infliximab (Remicade), which was the first chimeric monoclonal antibody against TNFα to be marketed for clinical use.
Etanercept is a dimeric molecule,[REF] and this dimeric structure is necessary for its proper therapeutic activity.